Yarrow Bioscience, Inc. Common Stock (YARW)

• Market cap: $20.3M
• 1 day: 0%
• 5 days: 25.1%
• 1 month: -6.42%
• 3 months: -4.37%
• 6 months: 7.56%
• Year to date: 5%
• 1 year: 52.94%
• 5 years: -98.75%
• 10 years: -99.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.